Ladenburg Thalmann Financial Services’s Akari Therapeutics AKTX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2	Closed	-$4K	–	5189
2018 Q3	$4K	Buy	+2	New	+$3.23K	﹤0.01%	4652

Other funds holding AKTX

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Ladenburg Thalmann Financial Services's AKTX Position: Q4 2018 in Review

Ladenburg Thalmann Financial Services sold out of Akari Therapeutics (AKTX) in Q4 2018, closing a stake of 2 shares — an estimated $4K sold.

Ladenburg Thalmann Financial Services first reported a position in AKTX in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 7 funds tracked by Wall St. Rank hold AKTX as of Q4 2018.

Ladenburg Thalmann Financial Services reported no remaining Akari Therapeutics position as of Q4 2018 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 2 Akari Therapeutics shares in Q4 2018, an estimated $4K.
Ladenburg Thalmann Financial Services first reported a position in Akari Therapeutics in Q3 2018 and held it in 1 quarter.
Ladenburg Thalmann Financial Services's Akari Therapeutics position peaked at $4K in Q3 2018.
7 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2018, filed 14 Feb 2019.